Comparisons of the risks of new-onset prostate cancer in type 2 diabetes mellitus between SGLT2I and DPP4I users: A population-based cohort study
Main finding · New-onset prostate cancerResult — go to the resultHazard ratio 0.45 95% CI 0.30–0.70Authors' conclusion
The study demonstrated SGLT2I was associated with lower risks of new-onset prostate cancer after propensity score matching and adjustments compared to DPP4I amongst T2DM patients.
Study context
- Population
- Male patients with T2D prescribed SGLT2i or DPP-4i, 1st January 2015 to 31st December 2020, Hong Kong; median age 61.0 years
- Participants
- 42,129 patients
- Exposure
- SGLT2i vs DPP-4i
- SGLT2In = 17,120
- DPP4In = 25,009reference
- Outcome
- New-onset prostate cancer
Methodological detailspropensity score matched (1:1), multivariable Cox regression
- Propensity score matched (1:1)
- Multivariable Cox regression
Main finding
As reported in the abstract
follow-up 5.61 years
Hazard ratio
0.45
95% CI 0.30–0.70
Events by group
SGLT2I
60
events
DPP4I
102
events
SGLT2Ivs DPP4I
HR 0.45 (95% CI 0.30–0.70)
Observational data: associations, not effects.
Secondary outcomes
Subgroup analyses (age, hypertension, HF, GLP-1a)
- Interactions between SGLT2I and age, hypertension, HF and GLP-1a not statistically significant
Sensitivity analysis
- Result remained consistent
Original publication
Comparisons of the risks of new-onset prostate cancer in type 2 diabetes mellitus between SGLT2I and DPP4I users: A population-based cohort study. Diabetes Metab. Published 23 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →